Objective. The goal of this study was to estimate the antitumor activity and toxicity of recombinant human interleukin-12 (rhIL-12) in patients with recurrent or refractory epithelial ovarian cancer. Methods. From December 1997 to March 1999, patients with recurrent or refractory epithelial ovarian cancer were entered on a Gynecologic Oncology Group phase II study of intravenous rhIL-12. All patients had measurable disease, had a performance status of 0-2, and had failed first-line platinum-based chemotherapy regimen. Eligible patients received rhIL-12, 250 ng/kg IV bolus, as a single dose on Day 1 followed by a 2-week rest period, with subsequent cycles administered daily for 5 days followed by a 16-day rest period per cycle, until disease progression or adverse effects prohibited further therapy. Results. Twenty-eight patients were entered and evaluable for toxicity, while 26 were evaluable for response. The median age was 59.5 years (range: 45-77). The median number of cycles was 2 (range: 1-9). There were no complete responders; however, one patient (3.8%) was a partial responder and 13 patients (50%) had stable disease. Grade 4 myelotoxicity occurred in 21% of patients. Two patients experienced capillary leak syndrome: one grade 2 and one grade 4. Conclusion. As a single agent, rhIL-12 is tolerable and shows a low response rate in recurrent epithelial cancer with measurable disease.

Aged↗

PubMed2001

Is this a way to choose a chair?

Explore the source record for details and available documents.

Faculty, Medical↗

PubMed2001

Cancer and pregnancy.

Carcinoma of the cervix is the most frequently diagnosed cancer in pregnancy. Still, it is an unusual situation. An abnormal Pap smear during pregnancy is a much more common occurrence and fortunately one that can be managed conservatively. Although definitive treatment for intraepithelial disease can be delayed until the postpartum period, diagnostic evaluation should be done when the abnormal Pap smear is present. Invasive cancer management is dependent on gestational age of the fetus. Pregnancy affords an excellent opportunity to screen for cervical neoplasia.

Female↗

PubMed2001